Puma Bio: Now Or Never. I Go With Never

|
About: Puma Biotechnology, Inc. (PBYI), Includes: DSKYF
by: James Charles Foord
This article is exclusive for subscribers.
Summary

Puma Biotech shares are trading at historical lows.

This can be attributed to subpar performance and direct competition from a newly approved drug.

However, Puma still has room to grow and the current valuation might be unwarranted.

Company Overview

Puma Biotechnology (PBYI) is a pharmaceutical company producing drugs used in cancer treatments. Their main product is Nerylinx, a compound used to treat breast cancer, specifically those that are HER-2 positive.